A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children with SCN1A-Positive Dravet Syndrome

Recruiting

Phase 1

Phase 2

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children with SCN1A-Positive Dravet SyndromeA Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children with SCN1A-Positive Dravet Syndrome

Sponsor:

Encoded Therapeutics

Code:

NCT05419492

Conditions

Dravet Syndrome

Eligibility Criteria

Sex: All

Age: 6 - 47

Healthy Volunteers: Not accepted

Interventions

ETX101

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information